CYTLIEVA 100 mg contains Cytarabine (Ara-C), a pyrimidine nucleoside analogue antimetabolite. It inhibits DNA polymerase, blocks DNA synthesis (S-phase specific), and leads to death of rapidly dividing leukemic cells. It is a cornerstone drug in acute leukemias.

Cytarabine is indicated for:

1. Acute Myeloid Leukemia (AML)

2. Acute Lymphoblastic Leukemia (ALL)

3. Chronic Myeloid Leukemia (CML) – blast crisis

4. Non-Hodgkin’s Lymphoma (selected regimens)

5. Meningeal Leukemia (intrathecal use – specific formulations)

Common side effects:

•  Severe myelosuppression

•  Nausea, vomiting

•  Mucositis

•  Alopecia

Other side effects:

•  Fever

•  Rash

High-dose related toxicity:

•  Cerebellar toxicity (ataxia, dysarthria)

•  Conjunctivitis

Requires close monitoring of CBC, liver & renal function, and neurological status in high doses.

Dosage depends on indication and treatment protocol.

Common dosing:

•  Standard dose:
    – 100–200 mg/m²/day as continuous IV infusion for 7 days

•  High-dose therapy:
    – 1–3 g/m² IV every 12 hours (specialized protocols)

100 mg vial is widely used for induction and consolidation regimens.

NOTE: This medicine should be taken only under a doctor’s supervision.